Last edition
News about "HRR-mutated Metastatic Prostate Cancer"
Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer
Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).
HRR-mutated Metastatic Prostate Cancer | 21/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members